TKNOHealthcare · Drug Manufacturers - Specialty & GenericThe 8 Wall Street analysts covering Alpha Teknova, Inc. hold a median 12-month price target of $9.5 — +21.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 94 of 100 as at 27 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Alpha Teknova, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (94): Analysts have, on balance, been raising their forecasts.
Volatility (28): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on TKNO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +21.1% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 13 Oct 2026 | TD Cowen | Maintains | Buy | $7.00 → $11 |
| 17 Sept 2026 | Jefferies | Initiates | Buy | $9.00 |
| 17 Sept 2026 | Jefferies | Initiates | Buy | — |
| 11 Aug 2026 | BTIG | Upgrade | Buy | $8.00 |
| 11 Aug 2026 | BTIG | Upgrade | Buy | — |
| 5 Aug 2026 | Roth Capital | Initiates | Buy | $7.00 |
| 5 Aug 2026 | Roth Capital | Initiates | Buy | — |
| 10 July 2024 | Stephens & Co. | Reiterates | Overweight | $5.00 |
| 10 July 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 14 May 2024 | Stephens & Co. | Reiterates | Overweight | — |
| 12 Mar 2024 | BTIG | Downgrade | Neutral | — |
| 12 July 2023 | Keybanc | Initiates | Sector Weight | — |
| 29 June 2023 | BTIG | Assumes | Buy | $6.00 |
| 11 Aug 2022 | Stephens & Co. | Maintains | Overweight | — |
| 16 Mar 2022 | Stephens & Co. | Maintains | Overweight | — |
| 20 July 2021 | BTIG | Initiates | Buy | — |
| 20 July 2021 | Cowen & Co. | Initiates | Outperform | — |
| 20 July 2021 | Stephens & Co. | Initiates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
TKNO appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, Alpha Teknova, Inc. returned +45.8% against +13.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 14% of US stocks
Cheaper than 16% of US stocks
Cheaper than 93% of US stocks
Higher than 67% of US stocks
Higher than 57% of US stocks
Higher than 49% of US stocks
Higher than 21% of US stocks
Higher than 12% of US stocks
Higher than 30% of US stocks
Higher than 27% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Alpha Teknova, Inc. has a market value of $438.7M and an enterprise value of $391.7M.
Revenue in the twelve months to 30 June 2026: $43.7M. The latest quarter grew 18.5% year on year.
Net income over the same four quarters: −$16.8M, a −38.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.31.
Free cash flow in the twelve months to 30 June 2026: −$7.4M.
Trailing P/E: −24.0×; forward P/E: −40.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Alpha Teknova, Inc. employs 158 people — $277K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Alpha Teknova, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Alpha Teknova shares rose 5.1% in the latest session on higher-than-average trading volume. The article notes that earnings estimate revisions may not support further near-term gains.
Why it matters — TKNO watchers may weigh the session's price and volume move against the article's caution about earnings estimate revisions.
Alpha Teknova announced that it will report financial results for the third quarter ended September 30, 2026, after market close on November 4, 2026.
Why it matters — TKNO watchers can note the scheduled date for the company’s third-quarter financial results.
Alpha Teknova priced an underwritten public offering of 8 million common shares at $5.00 per share, for expected gross proceeds of $40 million before discounts, commissions, and expenses. The company also granted underwriters a 30-day option to purchase up to 1.2 million additional shares; closing is expected around October 22, 2026, subject to customary conditions.
Why it matters — TKNO watchers may note the offering’s expected proceeds and the potential for up to 1.2 million additional shares to be sold.
Alpha Teknova announced that it has commenced an underwritten public offering of its common stock, with all offered shares to be sold by the company. It intends to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered; completion, size, and terms remain subject to conditions.
Why it matters — TKNO watchers may track the proposed offering because it would involve the company selling shares, though its final size and terms are not yet known.
Alpha Teknova announced preliminary, unaudited financial results for the three months ended September 30, 2026, in conjunction with filing a preliminary prospectus supplement.
Why it matters — The announcement provides TKNO watchers with an update on the company’s quarterly financial reporting.
The 8 Wall Street analysts covering Alpha Teknova, Inc. have a median 12-month price target of $9.5, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 8 analysts covering Alpha Teknova, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alpha Teknova, Inc. 94 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, Alpha Teknova, Inc. ranks 94 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (94 of 100).
No one can know that. What the data says: the median 12-month target from 8 analysts implies +21.1% from the last close, and Ticker Nerd's factor model ranks Alpha Teknova, Inc. 94 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Alpha Teknova, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TKNO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.
Alpha Teknova, Inc. returned +45.8% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Alpha Teknova, Inc. is a life sciences reagents company that develops and manufactures products used in research, bioprocessing, and molecular diagnostics.
The most recent item we track (Zacks Investment Research, 23 Oct 2026): "Alpha Teknova (TKNO) Stock Jumps 5.1%: Will It Continue to Soar?". Alpha Teknova shares rose 5.1% in the latest session on higher-than-average trading volume. The article notes that earnings estimate revisions may not support further near-term gains.
Alpha Teknova, Inc. is a life sciences reagents company that develops and manufactures products used in research, bioprocessing, and molecular diagnostics. Its offerings include pre-poured media plates for cell growth and cloning, liquid cell culture media and supplements, and molecular biology reagents for sample manipulation, resuspension, and purification. The company serves a broad customer base across the biotechnology, pharmaceutical, diagnostics, academic, and government research markets, supporting workflows tied to drug development, vaccine development, and advanced therapies. Alpha Teknova also provides custom and catalog solutions designed for laboratory and manufacturing applications, with products used in cell and gene therapy, synthetic biology, and other life science workflows. Headquartered in Hollister, California, Alpha Teknova plays a specialized role in the supply chain that enables scientific research and the production of biopharmaceutical products.
CEO Mr. Stephen Gunstream · 158 employees · United States · https://www.teknova.com
